Weiss Ratings Reaffirms "Sell (E+)" Rating for Tvardi Therapeutics (NASDAQ:TVRD)

Key Points

• Weiss Ratings has reaffirmed a "Sell (E+)" rating for Tvardi Therapeutics (NASDAQ:TVRD), indicating concerns about the company's stock performance.
• Multiple analysts have recently revised their ratings, with Cantor Fitzgerald downgrading to "neutral" and BTIG Research significantly lowering their target price from $55.00 to $15.00 while maintaining a "buy" rating.
• The stock experienced an increase of 2.1% in trading, reaching $6.83, but still reflects a challenging environment with analysts holding a consensus rating of "Hold" and an average target price of $55.50.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report)'s stock had its "sell (e+)" rating restated by Weiss Ratings in a research report issued on Tuesday,Weiss Ratings reports.

TVRD has been the topic of a number of other research reports. Cantor Fitzgerald cut shares of Tvardi Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday. BTIG Research dropped their target price on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a "buy" rating on the stock in a report on Monday. Barclays set a $5.00 target price on shares of Tvardi Therapeutics and gave the company an "equal weight" rating in a report on Monday. Piper Sandler cut shares of Tvardi Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday. Finally, Raymond James Financial restated a "market perform" rating on shares of Tvardi Therapeutics in a report on Tuesday. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $55.50.

Tvardi Therapeutics Trading Up 2.1%

Shares of TVRD stock traded up $0.14 during mid-day trading on Tuesday, reaching $6.83. 1,112,298 shares of the company's stock traded hands, compared to its average volume of 75,010. Tvardi Therapeutics has a 12 month low of $5.65 and a 12 month high of $43.65. The firm's 50-day simple moving average is $31.63.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($1.00) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%.

Hedge Funds Weigh In On Tvardi Therapeutics

Hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC purchased a new position in Tvardi Therapeutics in the 2nd quarter worth about $2,617,000. Marshall Wace LLP purchased a new position in Tvardi Therapeutics in the 2nd quarter worth about $583,000. Bank of America Corp DE purchased a new position in Tvardi Therapeutics in the 2nd quarter worth about $399,000. New York State Common Retirement Fund purchased a new position in Tvardi Therapeutics in the 2nd quarter worth about $92,000. Finally, Headlands Technologies LLC purchased a new position in Tvardi Therapeutics in the 2nd quarter worth about $80,000. Hedge funds and other institutional investors own 44.66% of the company's stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.